Wexner will use Paige’s FDA-approved AI-powered pathology algorithm — Paige Prostate Suite — to analyze the changes in prostate cancer diagnoses when AI is utilized. The multiarm clinical utility and health economics study will focus on how AI tools can improve the accuracy, efficiency and costs surrounding diagnosing cancer in a community hospital setting.
Paige Prostate Suite has demonstrated success in enhancing prostate cancer detection, and the study will examine how the tool helps general surgical pathologists detect, grade and quantify prostate cancers. The study will account for patient treatment and management pathways, subspecialist access and level of confidence in traditional and AI-assisted diagnosis, according to an Aug. 17 press release from Paige.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
